Show simple item record

A prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract.

dc.contributor.authorSteward, William P
dc.contributor.authorHarris, Martin
dc.contributor.authorWagstaff, John
dc.contributor.authorScarffe, J Howard
dc.contributor.authorDeakin, David P
dc.contributor.authorTodd, Ian D
dc.contributor.authorCrowther, Derek
dc.date.accessioned2010-12-02T11:54:27Z
dc.date.available2010-12-02T11:54:27Z
dc.date.issued1985-10
dc.identifier.citationA prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract. 1985, 21 (10):1195-200 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379
dc.identifier.pmid3841067
dc.identifier.doi10.1016/0277-5379(85)90015-X
dc.identifier.urihttp://hdl.handle.net/10541/116919
dc.description.abstractThirty-six patients presenting with stage II-IV primary gastrointestinal non-Hodgkin's lymphoma of high-grade pathology were treated in a prospective study from 1975 to 1983 with combined modality therapy. A complete response rate of 56% was obtained and the overall 5-yr survival rate was 36%. The 5-yr relapse-free survival rate of the complete remitters was 79%. Multivariate analysis revealed that the remission achieved (P less than 0.001) and the completeness of primary surgery (P = 0.018) would reliably predict the duration of overall survival. The finding of diffuse histiocytic histology (Rappaport) predicted longer relapse-free survival. The majority of deaths were related to intra-abdominal complications and not to disseminated lymphoma. Gastrointestinal tract non-Hodgkin's lymphoma of high-grade pathology of all stages is curable with a combination of chemotherapy and radiotherapy following surgery to remove as much macroscopic disease as is possible.
dc.language.isoenen
dc.subjectAnticancerous Combined Chemotherapyen
dc.subjectGastrointestinal Canceren
dc.subjectCancer Stagingen
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCombined Modality Therapy
dc.subject.meshDoxorubicin
dc.subject.meshFemale
dc.subject.meshGastrointestinal Neoplasms
dc.subject.meshHumans
dc.subject.meshLymphoma
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshProcarbazine
dc.subject.meshProspective Studies
dc.subject.meshVincristine
dc.titleA prospective study of the treatment of high-grade histology non-Hodgkin's lymphoma involving the gastrointestinal tract.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology and Departments of Histopathology and Radiotherapy, Christie Hospital, Wilmslow Road, Manchester, UKen
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
html.description.abstractThirty-six patients presenting with stage II-IV primary gastrointestinal non-Hodgkin's lymphoma of high-grade pathology were treated in a prospective study from 1975 to 1983 with combined modality therapy. A complete response rate of 56% was obtained and the overall 5-yr survival rate was 36%. The 5-yr relapse-free survival rate of the complete remitters was 79%. Multivariate analysis revealed that the remission achieved (P less than 0.001) and the completeness of primary surgery (P = 0.018) would reliably predict the duration of overall survival. The finding of diffuse histiocytic histology (Rappaport) predicted longer relapse-free survival. The majority of deaths were related to intra-abdominal complications and not to disseminated lymphoma. Gastrointestinal tract non-Hodgkin's lymphoma of high-grade pathology of all stages is curable with a combination of chemotherapy and radiotherapy following surgery to remove as much macroscopic disease as is possible.


Files in this item

This item appears in the following Collection(s)

Show simple item record